Applied DNA Receives Notice of Allowance for Key U.S. Patent

STONY BROOK, NY / ACCESSWIRE / June 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN), a leader in PCR-based DNA technologies, announced it received a Notice of Allowance from the USPTO for patent application 18/302,247, entitled "Compositions and Methods for RNA Synthesis."

The patent will cover the composition of the company's chemically modified RNA polymerase enzyme, branded Linea™ RNAP, until 2041. This enzyme is a core component of the Linea™ IVT platform, which enables more efficient mRNA production with reduced double-stranded RNA contamination. Applied DNA acquired the technology via its acquisition of Spindle Bio, Inc. in July 2023.

Dr. James A. Hayward, CEO of Applied DNA, highlighted the significance of this patent allowance in tandem with the company's advancing GMP capabilities. He noted the potential to capture market share amid the development of approximately 450 mRNA therapies globally, many in the preclinical stage.